Efficacy and safety of axitinib for metastatic renal cell carcinoma : real-world data on patients with renal impairment

Minami, Keita; Osawa, Takahiro; Kojima, Takahiro; Hara, Tomohiko; Eto, Masatoshi; Takeuchi, Ario; Nakai, Yasutomo; Ueda, Kosuke; Ozawa, Michinobu; Uemura, Motohide; Ohba, Kojiro; Tamura, Keita; Shindo, Tetsuya; Nakagomi, Hiroshi; Takahashi, Atsushi; Anai, Satoshi; Yokomizo, Akira; Morizane, Shuichi; Kimura, Takahiro; Shimazui, Toru; Miyauchi, Yasuyuki; Mitsuzuka, Koji; Hara, Hiroaki; Yoshimura, Koji; Shiina, Hiroaki; Ito, Youichi M.; Murai, Sachiyo; Nishiyama, Hiroyuki; Shinohara, Nobuo; Kitamura, Hiroshi

Efficacy and safety of axitinib for metastatic renal cell carcinoma : real-world data on patients with renal impairment

Minami, Keita; Osawa, Takahiro; Kojima, Takahiro et al.

Urologic Oncology : Seminars and Original Investigations, 2023, 41(11), 458.e9-458.e19

Permalink : https://hdl.handle.net/2115/93757

このアイテムのアクセス数:200件（2026-10-07 00:14 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数
HUSCAP_311453-text_axitinib_0731	pdf	592 KB	190
Table S1_R	docx	16.0 KB	45
Table S2_R	docx	15.9 KB	38
Supl figure 1	TIF	79.4 KB	23

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/93757
タイトル	Efficacy and safety of axitinib for metastatic renal cell carcinoma : real-world data on patients with renal impairment
著者	Minami, Keita ; Osawa, Takahiro ; Kojima, Takahiro ; Hara, Tomohiko ; Eto, Masatoshi ; Takeuchi, Ario ; Nakai, Yasutomo ; Ueda, Kosuke ; Ozawa, Michinobu ; Uemura, Motohide ; Ohba, Kojiro ; Tamura, Keita ; Shindo, Tetsuya ; Nakagomi, Hiroshi ; Takahashi, Atsushi ; Anai, Satoshi ; Yokomizo, Akira ; Morizane, Shuichi ; Kimura, Takahiro ; Shimazui, Toru ; Miyauchi, Yasuyuki ; Mitsuzuka, Koji ; Hara, Hiroaki ; Yoshimura, Koji ; Shiina, Hiroaki ; Ito, Youichi M. ; Murai, Sachiyo ; Nishiyama, Hiroyuki ; Shinohara, Nobuo ; Kitamura, Hiroshi
著者名 Minami, Keita
e-Rad_Researcher 60374443 著者名 Osawa, Takahiro
著者名 Kojima, Takahiro
著者名 Hara, Tomohiko
著者名 Eto, Masatoshi
著者名 Takeuchi, Ario
著者名 Nakai, Yasutomo
著者名 Ueda, Kosuke
著者名 Ozawa, Michinobu
著者名 Uemura, Motohide
著者名 Ohba, Kojiro
著者名 Tamura, Keita
著者名 Shindo, Tetsuya
著者名 Nakagomi, Hiroshi
著者名 Takahashi, Atsushi
著者名 Anai, Satoshi
著者名 Yokomizo, Akira
著者名 Morizane, Shuichi
著者名 Kimura, Takahiro
著者名 Shimazui, Toru
著者名 Miyauchi, Yasuyuki
著者名 Mitsuzuka, Koji
著者名 Hara, Hiroaki
著者名 Yoshimura, Koji
著者名 Shiina, Hiroaki
著者名 Ito, Youichi M.
著者名 Murai, Sachiyo
著者名 Nishiyama, Hiroyuki
e-Rad_Researcher 90250422 著者名 Shinohara, Nobuo
著者名 Kitamura, Hiroshi
言語	英語
キーワード	Renal cell carcinoma
	Metastatic
	Axitinib
	Renal impairment
発行日	2023-12
出版者	Elsevier
収録物名	Urologic Oncology : Seminars and Original Investigations
巻(号)	41(11)
ページ	458.e9-458.e19
抄録	Objectives Limited information is currently available on the efficacy and safety of axitinib for metastatic renal cell carcinoma (mRCC) patients with renal impairment. Therefore, the present study investigated the efficacy and toxicity of axitinib in patients with chronic kidney disease. Methods Post-hoc analyses were performed on a Japanese multicenter cohort study of 477 mRCC patients who received axitinib followed by 1 or 2 regimens of systemic antiangiogenic therapy between January 2012 and December 2016. Differences in clinical characteristics and the efficacy and safety of axitinib were assessed based on pretreatment renal function. Results Patients were categorized into the following 5 renal function groups according to baseline renal function: estimated glomerular filtration rate (eGFR) ≥60 ml/min (n = 133), 45 ml/min ≤eGFR <60 ml/min (n = 153), 30 ml/min ≤eGFR< 45 ml/min (n = 130), eGFR <30 ml/min (n = 45), and dialysis (n = 16). Median progression-free survival (PFS) (95% confidence interval [CI]) in the 5 groups was 11 (8−16), 14 (11−19), 14 (10–19), 12 (8−24), and 6 (3-NR) months, respectively (p = 0.781). After adjustments for treatment-related confounders, the renal function group was not a significant prognostic factor for PFS. Objective response rates in the 5 groups were 22%, 23%, 23%, 18%, 20%, and 38%, respectively (p = 0.468). Regarding adverse events of all grades, hypertension (p = 0.0006) and renal and urinary disorders (p < 0.0001) were more frequently observed in the eGFR <30 ml/min group than in the other groups. Conclusions Since renal function at the initiation of treatment with axitinib does not adversely affect the efficacy of VEGF-TKI therapy, clinicians do not need to avoid its administration to mRCC patients with impaired renal function in consideration of the risk of progression to end-stage renal disease.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2023. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	1078-1439
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.urolonc.2023.08.008